GlassScriptPhysician profile
Kimberly E Wilson
NPI 1285826057
$1,848.61
in general payments reported to CMS, 2019-2025
21 companies · $68.73 in 2025
The $68.73 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $543 · 2022: $592 · 2023: $417 · 2024: $228 · 2025: $68.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $713.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $750.27 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $173.55 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $163.60 | 2021-2023 | |
| Abbott Laboratories | $87.76 | 2024 | Freestyle Libre 3 |
| Daiichi Sankyo INC. | $85.19 | 2021-2023 | Injectafer |
| Janssen Pharmaceuticals, INC | $79.49 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.29 | 2022-2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $61.60 | 2022 | |
| Currax Pharmaceuticals LLC | $60.83 | 2021-2023 | Contrave |
| Pfizer INC. | $58.69 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.52 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.37 | 2024 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $37.72 | 2022-2023 | |
| Corium, LLC | $22.30 | 2025 | Azstarys |
| Biohaven Pharmaceuticals, INC. | $22.03 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $19.20 | 2021 | |
| Atland Pharmaceuticals, LLC | $16.50 | 2025 | Orphenadrine Citrate, Aspirin and Caffeine, Tolmetin Sodium |
| Astellas Pharma US INC | $15.68 | 2023 | Myrbetriq |
| Exact Sciences Corporation | $15.63 | 2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $14.54 | 2024 | Breztri |
| Genentech USA, INC. | $9.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.